Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;86:607-609

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abe, J.-i.
Right arrow Articles by Berk, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abe, J.-i.
Right arrow Articles by Berk, B. C.
Related Collections
Right arrow Contractile function
Right arrow Apoptosis
Right arrow Ischemic biology - basic studies
(Circulation Research. 2000;86:607.)
© 2000 American Heart Association, Inc.


Editorials

Role of Mitogen-Activated Protein Kinases in Ischemia and Reperfusion Injury

The Good and the Bad

Jun-ichi Abe, Christopher P. Baines, Bradford C. Berk

From the Center for Cardiovascular Research, University of Rochester, Rochester, NY.

Correspondence to Bradford C. Berk, MD, PhD, Cardiology Unit, Box 679, 601 Elmwood Ave, Rochester, NY 14642. E-mail Bradford_Berk{at}urmc.rochester.edu


Key Words: ischemia/reperfusion • mitogen-activated protein kinase • apoptosis • cardiomyocyte


*    Introduction
up arrowTop
*Introduction
down arrowMAP Kinases
down arrowJNK and p38: Proapoptotic...
down arrowERK1 and BMK1: Antiapoptotic...
down arrowApoptosis, Necrosis, and Cardiac...
down arrowReferences
 
There is growing evidence that multiple mitogen-activated protein (MAP) kinases are activated during ischemia and/or reperfusion and may contribute to the structural and functional changes after myocardial ischemia. A new study by Yue et al1 in this issue of Circulation Research attempts to address the role of MAP kinases in ischemic myocardium and suggests that ERK1/ERK2 is part of a "survival" pathway whereas p38 and JNK mediate a "death" pathway in the ischemic myocardium.

Myocyte loss during the acute stage of myocardial infarction involves both apoptotic and necrotic cell death.2 3 4 Therefore, it is reasonable to think that the balance of cell survival and death is critical during the pathological evolution of postischemic cardiac dysfunction. Recently, many scientists seeking to elucidate the intricate relationship between signal transduction and this balance of survival and death in ischemic myocardium have focused on MAP kinases.


*    MAP Kinases
up arrowTop
up arrowIntroduction
*MAP Kinases
down arrowJNK and p38: Proapoptotic...
down arrowERK1 and BMK1: Antiapoptotic...
down arrowApoptosis, Necrosis, and Cardiac...
down arrowReferences
 
MAP kinases are highly conserved serine/threonine kinases that are activated in response to a wide variety of stimuli including growth factors, G protein–coupled receptors, and environmental stresses.5 Consequently, they play a role in numerous cell functions including growth and proliferation. The MAP kinases themselves require dual phosphorylation on a Thr-X-Tyr motif to become active. Three major MAP kinase cascades have been extensively studied in the heart: extracellular signal–regulated kinases (ERK1 and ERK2), c-Jun N-terminal kinases (JNK1 and JNK2), and p38 kinases, of which the p38{alpha} and p38ß isoforms are found in the heart.5 Recently, a fourth MAP kinase member, big MAPK-1 (BMK1, also known as ERK5), has been identified in cardiac tissue (FigureDown).6



View larger version (21K):
[in this window]
[in a new window]
 
Figure 1. MAP kinases pathway.


*    JNK and p38: Proapoptotic Bad Guys?
up arrowTop
up arrowIntroduction
up arrowMAP Kinases
*JNK and p38: Proapoptotic...
down arrowERK1 and BMK1: Antiapoptotic...
down arrowApoptosis, Necrosis, and Cardiac...
down arrowReferences
 
The pathways regulated by p38 and JNK contribute importantly to apoptosis. The mechanisms by which p38 and JNK induce apoptosis are largely cell and stimulus specific. For example, apoptosis in response to deprivation of growth factors principally involves the activation of p38 rather than JNK.7 In some cells,8 JNK-mediated apoptosis has been shown to involve ubiquitination and degradation of p53, which may be regulated by JNK-mediated phosphorylation of p53.8 However, p53 does not appear to be important for hypoxia-induced apoptosis in cardiac myocytes. Webster et al9 reported that cell death mediated by hypoxia combined with acidosis was independent of p53 because there was no significant difference between apoptosis occurrence in hearts from wild-type mice and p53 knockout mice. Thus, the mechanism for JNK-induced apoptosis in the heart remains unexplained.

The role of p38 in myocyte apoptosis is puzzling because p38 can also mediate cardiac hypertrophy. One of the ways that p38 can induce apoptosis is through its effect on cyclin D1 expression during cell cycle. It has been demonstrated that the coexpression of MKK3 along with p38 inhibits mitogen-induced cyclin D1 expression.10 However, evidence implies a protective role for p38 during ischemia: p38 phosphorylates MAPKAPK2, which in turn phosphorylates HSP27.11 Activation of this pathway is cytoprotective, and overexpression of HSP27 confers protection against ischemia in myocytes.12 13 Protection by ischemic preconditioning also appears to be dependent on p38 activation,14 and direct activation of p38 and JNK by anisomycin is cardioprotective.14 Activation of different p38 isoforms may explain these findings; p38{alpha} may be proapoptotic, whereas p38ß may be antiapoptotic in rat neonatal ventricular myocytes.15 In summary, the current data for p38 and JNK suggest multiple roles in ischemia, reperfusion, preconditioning, and hypertrophy. Defining their precise roles and interaction will require cardiac-specific p38 and JNK knockout mice.


*    ERK1 and BMK1: Antiapoptotic Good Guys?
up arrowTop
up arrowIntroduction
up arrowMAP Kinases
up arrowJNK and p38: Proapoptotic...
*ERK1 and BMK1: Antiapoptotic...
down arrowApoptosis, Necrosis, and Cardiac...
down arrowReferences
 
Although ERK1/ERK2 was the first MAP kinase described, a closely related member BMK1 (ERK5) has recently been identified.16 17 Both ERK1/ERK2 and BMK1 activation are protective against apoptotic cell death. Among the substrates of ERK, special attention should be given to p90 ribosomal S6 kinase (p90RSK), which is a ubiquitous and versatile mediator of ERK signal transduction.18 Essential functions of p90RSK include (1) regulation of gene expression via phosphorylation of transcription factors including c-Fos and cAMP-response element-binding (CREB) protein; (2) regulation of protein synthesis by phosphorylation of polyribosomal proteins and glycogen synthase kinase-3; and (3) stimulation of Na+-H+ exchanger by phosphorylating serine 703 of NHE-1.19 Recently Bonni et al20 and Tan et al21 reported that p90RSK phosphorylated the proapoptotic protein BAD at serine 112, which specifically suppressed BAD-mediated apoptosis. These findings suggest that p90RSK and ERK promote cell survival by both inhibiting components of the cell death machinery (eg, BAD) and increasing transcription of prosurvival genes (eg, CREB) (FigureUp).

In the study by Yue et al,1 the authors concluded that ERK1/ERK2 is important for myocyte survival in ischemic myocardium based on the effect of the MEK-1 inhibitor PD98059. However, the use of PD98059 as a selective MEK1/MEK2 inhibitor is not as safe as previously thought. Recently, this compound was found to inhibit the activation of BMK1 as well as ERK.22 MEK5 and BMK1 are highly expressed in cardiac myocytes.16 Importantly, BMK1 has also been proposed to be antiapoptotic based on results of MEK5 inhibition.23 MEK5-dependent BMK1 activation results in the phosphorylation of MEF2A and MEF2C, transcription factors that belong to the myocyte enhancer factor-2 (MEF2) family,24 which are important regulators of cardiac gene expression. Because BMK1 can also be activated in the ischemic myocardium,6 it will be necessary to evaluate the role of this MAP kinase in PD98059-induced survival.


*    Apoptosis, Necrosis, and Cardiac Function
up arrowTop
up arrowIntroduction
up arrowMAP Kinases
up arrowJNK and p38: Proapoptotic...
up arrowERK1 and BMK1: Antiapoptotic...
*Apoptosis, Necrosis, and Cardiac...
down arrowReferences
 
Yue et al1 chose apoptosis as their endpoint of cell death as opposed to necrosis. Until recently, it was accepted that irreversible cell death in the ischemic myocardium was due to necrosis. However, evidence has accumulated over the last decade indicating that cardiac myocytes are capable of undergoing apoptosis and that this process may play a role in ischemic injury of the heart.25 Interestingly, it appears that both ischemia and reperfusion are required to induce apoptosis; ischemia alone is insufficient as shown in both the present and previous studies.1 25 However, the degree to which apoptosis contributes to myocardial damage is a hotly debated issue that may be due in part to the techniques used for detecting apoptosis. Studies have shown that assays thought to be apoptosis specific can also detect necrotic cells, thus potentially overestimating the number of apoptotic myocytes.26 The fact that apoptosis occurs over several hours to days (as opposed to necrosis, which can occur in minutes) casts doubts as to whether this form of death contributes to the acute functional change associated with infarction.

The present study challenges this concept because Yue et al1 showed significant improvement of cardiac function after global ischemia within only 1 hour of reperfusion using SB203580, a p38 inhibitor. In a similar study the authors also found that apoptosis could be detected after only 1 hour of reperfusion, and this was reversed by SB203580.27 These data would indicate that the improvement of cardiac function is directly correlated with the prevention of apoptosis. However, SB203580 also reduced infarction so that p38 may have other effects on cardiac function unrelated to apoptosis. We propose that the posttranslational effects of MAP kinases, such as phosphorylation of NHE-1 and BAD, contribute to the protective effects in early cardiac function recovery, perhaps to a greater extent than alternations in gene expression and apoptosis (FigureUp).


*    Footnotes
 
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.


*    References
up arrowTop
up arrowIntroduction
up arrowMAP Kinases
up arrowJNK and p38: Proapoptotic...
up arrowERK1 and BMK1: Antiapoptotic...
up arrowApoptosis, Necrosis, and Cardiac...
*References
 

  1. Yue T-L, Wang C, Gu J-L, Ma X-L, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH. Inhibition of extracellular signal–regulated kinase enhances ischemia/reoxygenation–induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000;86:692–699.[Abstract/Free Full Text]
  2. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K. DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol. 1995;146:1325–1331.[Abstract]
  3. Bardales RH, Hailey LS, Xie SS, Schaefer RF, Hsu SM. In situ apoptosis assay for the detection of early acute myocardial infarction. Am J Pathol. 1996;149:821–829.[Abstract]
  4. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320–323.[Abstract/Free Full Text]
  5. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345–352.[Free Full Text]
  6. Takeishi Y, Abe J, Lee JD, Kawakatsu H, Walsh RA, Berk BC. Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused guinea pig hearts. Circ Res. 1999;85:1164–1172.[Abstract/Free Full Text]
  7. Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 1997;272:20490–20494.[Abstract/Free Full Text]
  8. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A. 1998;95:10541–10546.[Abstract/Free Full Text]
  9. Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B, Bishopric NH. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest. 1999;104:239–252.[Medline] [Order article via Infotrieve]
  10. Lavoie JN, L’Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608–20616.[Abstract/Free Full Text]
  11. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, Saklatvala J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell. 1994;78:1039–1049.[Medline] [Order article via Infotrieve]
  12. Huot J, Houle F, Marceau F, Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res. 1997;80:383–392.[Abstract/Free Full Text]
  13. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation. 1997;96:4343–4348.[Abstract/Free Full Text]
  14. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV, Critz SD. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res. 2000;86:144–151.[Abstract/Free Full Text]
  15. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161–2168.[Abstract/Free Full Text]
  16. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem. 1995;270:12665–12669.[Abstract/Free Full Text]
  17. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian MAP kinase. Biochem Biophys Res Commun. 1995;213:715–724.[Medline] [Order article via Infotrieve]
  18. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol. 1999;151:65–77.[Medline] [Order article via Infotrieve]
  19. Takahashi E, Abe J, Gallis B, Aebersold R, Spring DJ, Krebs EG, Berk BC. p90RSK is a serum-stimulated NHE1 kinase: regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. J Biol Chem. 1999;274:20206–20214.[Abstract/Free Full Text]
  20. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358–1362.[Abstract/Free Full Text]
  21. Tan Y, Ruan H, Demeter MR, Comb MJ. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem. 1999;274:34859–34867.[Abstract/Free Full Text]
  22. Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999;274:26563–26571.[Abstract/Free Full Text]
  23. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 1998;395:713–716.[Medline] [Order article via Infotrieve]
  24. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 1997;16:7054–7066.[Medline] [Order article via Infotrieve]
  25. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;82:1111–1129.[Free Full Text]
  26. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, Fujiwara T, Fujiwara H. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with in situ nick end-labeling. Circulation. 1998;98:1422–1430.[Abstract/Free Full Text]
  27. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, Yue TL. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685–1691.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
P. S. Wolf, H. E. Merry, A. S. Farivar, A. S. McCourtie, and M. S. Mulligan
Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 656 - 665.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Morisco, C. Marrone, V. Trimarco, S. Crispo, M. G. Monti, J. Sadoshima, and B. Trimarco
Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression
Cardiovasc Res, December 1, 2007; 76(3): 453 - 464.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. A. Wall, J. Wei, M. Ly, P. Belmont, J. J. Martindale, D. Tran, J. Sun, W. J. Chen, W. Yu, P. Oeller, et al.
Alterations in oxidative phosphorylation complex proteins in the hearts of transgenic mice that overexpress the p38 MAP kinase activator, MAP kinase kinase 6
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2462 - H2472.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
N. C. Weber, J. Stursberg, N. M. Wirthle, O. Toma, W. Schlack, and B. Preckel
Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo
Br. J. Anaesth., September 1, 2006; 97(3): 298 - 306.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
D. K. Das and N. Maulik
Resveratrol in cardioprotection: a therapeutic promise of alternative medicine.
Mol. Interv., February 1, 2006; 6(1): 36 - 47.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H.-F. Su, A. Samsamshariat, J. Fu, Y.-X. Shan, Y.-H. Chen, D. Piomelli, and P. H. Wang
Oleylethanolamide Activates Ras-Erk Pathway and Improves Myocardial Function in Doxorubicin-Induced Heart Failure
Endocrinology, February 1, 2006; 147(2): 827 - 834.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Okada, H. Otani, Y. Wu, S. Kyoi, C. Enoki, H. Fujiwara, T. Sumida, R. Hattori, and H. Imamura
Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2310 - H2318.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Sumida, H. Otani, S. Kyoi, T. Okada, H. Fujiwara, Y. Nakao, M. Kido, and H. Imamura
Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2726 - H2734.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. J. Martindale, J. A. Wall, D. M. Martinez-Longoria, P. Aryal, H. A. Rockman, Y. Guo, R. Bolli, and C. C. Glembotski
Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo
J. Biol. Chem., January 7, 2005; 280(1): 669 - 676.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D.-G. Cho, M. R. Mulloy, P. A. Chang, M. D. Johnson, A. S. Aharon, T. A. Robison, T. L. Buckles, D. W. Byrne, and D. C. Drinkwater Jr
Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1033 - 1040.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Force, K. Kuida, M. Namchuk, K. Parang, and J. M. Kyriakis
Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease
Circulation, March 16, 2004; 109(10): 1196 - 1205.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Chen, R. Rajashree, Q. Liu, and P. Hofmann
Acute p38 MAPK activation decreases force development in ventricular myocytes
Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2578 - H2586.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. G. Souza, R. Guabiraba, V. Pinho, A. Bristow, S. Poole, and M. M. Teixeira
IL-1-Driven Endogenous IL-10 Production Protects Against the Systemic and Local Acute Inflammatory Response Following Intestinal Reperfusion Injury
J. Immunol., May 1, 2003; 170(9): 4759 - 4766.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. E. Regan, M. Broad, A. M. Byford, A. R. Lankford, R. J. Cerniway, M. W. Mayo, and G. P. Matherne
A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity
Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H859 - H866.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Pye, F. Ardeshirpour, A. McCain, D. A. Bellinger, E. Merricks, J. Adams, P. J. Elliott, C. Pien, T. H. Fischer, A. S. Baldwin Jr., et al.
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury
Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H919 - H926.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Ogita, K. Node, H. Asanuma, S. Sanada, Y. Liao, S. Takashima, M. Asakura, H. Mori, Y. Shinozaki, M. Hori, et al.
Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart
J. Am. Coll. Cardiol., September 4, 2002; 40(5): 998 - 1005.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Takeishi, Q. Huang, J.-i. Abe, W. Che, J.-D. Lee, H. Kawakatsu, B. D Hoit, Bradford.C Berk, and R. A Walsh
Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy
Cardiovasc Res, January 1, 2002; 53(1): 131 - 137.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das
Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning
Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. L. Martin, M. Avkiran, R. A. Quinlan, P. Cohen, and M. S. Marber
Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38{alpha} Mitogen-Activated Protein Kinase: Evidence From Ectopic Expression of an Inhibition-Resistant Kinase
Circ. Res., October 26, 2001; 89(9): 750 - 752.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abe, J.-i.
Right arrow Articles by Berk, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abe, J.-i.
Right arrow Articles by Berk, B. C.
Related Collections
Right arrow Contractile function
Right arrow Apoptosis
Right arrow Ischemic biology - basic studies